

1 **Prostaglandin E₂ induction by cytosolic *Listeria monocytogenes* in phagocytes is necessary**
2 **for optimal T-cell priming**

3
4 Courtney E. McDougal¹, Zachary T. Morrow¹, Seonyoung Kim², Drake Carter², David M.
5 Stevenson³, Daniel Amador-Noguez³, Mark J. Miller², John-Demian Sauer^{1,*}

6
7 1. Department of Medical Microbiology and Immunology, University of Wisconsin-Madison,
8 Madison, Wisconsin, United States of America

9 2. Department of Internal Medicine, Division of Infectious Diseases, Washington University
10 School of Medicine, St. Louis, Missouri, United States of America

11 3. Department of Bacteriology, University of Wisconsin-Madison, Madison, Wisconsin, United
12 States of America

13
14 * Corresponding Author

15 Email: sauer3@wisc.edu (JDS)

16 **Abstract**

17 *Listeria monocytogenes* is an intracellular bacterium that elicits robust CD8⁺ T-cell responses.
18 Despite the ongoing development of *L. monocytogenes*-based platforms as cancer vaccines, our
19 understanding of how *L. monocytogenes* drives robust CD8⁺ T-cell responses remains
20 incomplete. One overarching hypothesis is that activation of cytosolic innate pathways is critical
21 for immunity, as strains of *L. monocytogenes* that are unable to access the cytosol fail to elicit
22 robust CD8⁺ T-cell responses and in fact inhibit optimal T-cell priming. Counterintuitively,
23 however, activation of known cytosolic pathways, such as the inflammasome and type I IFN,
24 lead to impaired immunity. Here, we describe a cytosol-dependent response that is critical for
25 immunity to *L. monocytogenes*, namely production of prostaglandin E₂ (PGE₂) downstream of
26 cyclooxygenase-2 (COX-2). Vacuole-constrained *L. monocytogenes* elicit reduced PGE₂
27 production compared to wild-type strains in macrophages and dendritic cells *ex vivo*. *In vivo*,
28 infection with wild-type *L. monocytogenes* leads to 10-fold increases in PGE₂ production early
29 during infection whereas vacuole-constrained strains fail to induce PGE₂ over mock-immunized
30 controls. Mice deficient in COX-2 specifically in Lyz2⁺ or CD11c⁺ cells produce less PGE₂,
31 suggesting these cell subsets contribute to PGE₂ levels *in vivo*, while depletion of phagocytes
32 with clodronate abolishes PGE₂ production completely. Taken together, this work identifies the
33 first known cytosol-dependent innate immune response critical for generating CD8⁺ T-cell
34 responses to *L. monocytogenes*, suggesting that one reason cytosolic access is required to prime
35 CD8⁺ T-cell responses may be due to induction of PGE₂.

36

37 **Author summary**

38 *L. monocytogenes* is an intracellular bacterial pathogen that generates robust cell-mediated
39 immune responses. Due to this robust induction, *L. monocytogenes* is used as both a model to
40 understand how CD8⁺ T-cells are primed, as well as a platform for cancer immunotherapy
41 vaccines. *L. monocytogenes* must enter the cytosol of an infected host cell to stimulate robust T-
42 cell responses, however, which cytosolic innate pathway(s) contribute to T-cell priming remains
43 unclear. Here, we define COX-2 dependent PGE₂ production as the first cytosol-dependent
44 innate immune response critical for immunity to *L. monocytogenes*. We found that *ex vivo* PGE₂
45 production by macrophages and dendritic cells is partially dependent on cytosolic access, as
46 vacuole-constrained strains of *L. monocytogenes* elicit reduced PGE₂. *In vivo*, cytosolic access is
47 essential for PGE₂ production. *L. monocytogenes* elicits a 10-fold increase in PGE₂ production,
48 whereas strains of *L. monocytogenes* that cannot access the cytosol fail to elicit PGE₂ compared
49 to mock immunized mice. Furthermore, CD11c⁺ and Lyz2⁺ cells contribute to PGE₂ production
50 *in vivo*, as mice deficient in COX-2 in these cell subsets have impaired PGE₂ production. Taken
51 together, our work identifies the first known cytosol-dependent pathway that is critical for
52 generating immunity to *L. monocytogenes*.

53 **Introduction**

54 *Listeria monocytogenes* is a Gram-positive, intracellular pathogen that elicits robust
55 CD8⁺ T-cell responses. Due to this robust response, *L. monocytogenes* has been used for decades
56 as a model to understand how CD8⁺ T-cell responses are primed[1]. Understanding these
57 responses has become more pressing recently as *Listeria*-based platforms aiming to drive CD8⁺
58 T-cell responses are in use as cancer immunotherapies[2]. Initial work showed that critical
59 signals promoting *Listeria*-stimulated T-cell responses are provided acutely, as bacterial
60 clearance with antibiotics as early as 24 hours-post infection has minimal impact on the kinetics
61 of CD8⁺ T-cell responses[3]. This work highlights the role of early signals in informing *Listeria*-
62 stimulated cell mediated adaptive responses.

63 One early signal impacting T-cell responses is the inflammatory environment induced
64 during infection. The importance of the inflammatory milieu on priming T-cell responses has
65 been solidified by multiple groups using antigen-pulsed, matured dendritic cells in combination
66 with non-antigen expressing *L. monocytogenes* as an inflammatory boost[4,5]. These studies
67 enable discrimination between antigen presentation and inflammation and demonstrate that wild-
68 type *L. monocytogenes* provides an optimal inflammatory milieu to drive T-cell priming[4,5].
69 The inflammatory boost provided through wild-type *L. monocytogenes* infection led to increased
70 T-cell responses, whereas use of strains that specifically alter the inflammatory milieu led to
71 suboptimal responses[4,5]. *L. monocytogenes* activates a number of innate pathways that
72 contribute to the inflammatory milieu. In particular, multiple groups have focused on the role of
73 various cytosolic innate immune pathways, as previous research demonstrated the necessity of
74 cytosolic access in priming cell-mediated immunity[6–8]. *L. monocytogenes* utilizes a cytolysin,
75 listeriolysin O (LLO), to escape from phagosomes directly into the cytosol and LLO-deficient

76 mutants that are unable to access the cytosol inhibit T-cell priming and generate tolerizing
77 immune responses[9,10]. Despite the importance of cytosolic access for priming T-cell
78 responses, multiple cytosol-dependent innate pathways are counterintuitively detrimental to
79 immunity including STING-dependent type I interferon[11,12] as well as inflammasome
80 activation[4,13]. We recently identified an alternative innate pathway, production of the
81 eicosanoid prostaglandin E₂ (PGE₂), as important for immunity as mice deficient in PGE₂ have
82 impaired acute and protective T-cell responses to *L. monocytogenes*[14]. Whether PGE₂
83 production is dependent on cytosolic access of *L. monocytogenes* remains unknown as is which
84 cells produce PGE₂ in response to *L. monocytogenes* infection.

85 Eicosanoids are lipid mediators of inflammation that have potent biological functions. A
86 major subset of these lipids, including PGE₂, are derived from arachidonic acid[15]. During
87 inflammation, arachidonic acid is liberated from the membrane by the cytosolic phospholipase
88 A2 (cPLA2) and then further metabolized by a number of enzymes including the P450
89 epoxygenase, lipoxygenases, and cyclooxygenases (COXs)[15]. During infection, PGE₂ is
90 produced downstream of COX enzymes, particularly downstream of cyclooxygenase-2 (COX-
91 2)[16]. COX-2 is induced during inflammation and functions to reduce arachidonic acid to
92 prostaglandin H₂ (PGH₂)[17,18]. PGH₂ is further metabolized into different prostaglandins by
93 terminal prostaglandin synthases. Coupling of COX enzymes with prostaglandin synthases
94 ultimately dictates which prostaglandin will be produced[17,18]. PGE₂ specifically is produced
95 by three different terminal synthases, the cytosolic prostaglandin E synthase (cPGES) and
96 microsomal prostaglandin E synthases-1 and -2 (mPGES-1 and mPGES-2)[16,19]. Of these
97 synthases, mPGES-1 is inducible and associated with infection due to its role in inflammatory
98 responses[16,19]. For example, mice deficient in mPGES-1 have reduced febrile and pain

99 responses[16,19]. Previously, we showed that *L. monocytogenes* infection of mice deficient in
100 mPGES-1 or use of a COX-2-specific inhibitor leads to impaired T-cell responses that could be
101 rescued by exogenous dosing of PGE₂[14]. Together, these data suggest that production of PGE₂
102 downstream of COX-2 and mPGES-1 is critical for immunity.

103 During *L. monocytogenes* infection, the cell types responsible for producing PGE₂ remain
104 unclear. *L. monocytogenes* is initially captured by a wide range of phagocytic antigen presenting
105 cells (APCs) in the marginal zone of the spleen[20]. Initially, *L. monocytogenes* highly infects
106 multiple macrophage subsets, including MOMA⁺ metallophilic and MARCO⁺ marginal zone
107 macrophages[20]. Later, *L. monocytogenes* infection transitions to splenic CD11c⁺ and CD11b⁺
108 cells in the white pulp[20]. Importantly, PGE₂ is produced at high amounts early in the immune
109 response, starting at four hours post immunization and peaking at twelve hours, early timepoints
110 during which macrophages and dendritic cells are heavily infected[14]. Furthermore, one
111 previous study demonstrated that peritoneal macrophages are capable of producing PGE₂ after *ex*
112 *vivo* infection with *L. monocytogenes*[21]. Further analysis is required to elucidate whether
113 macrophages and dendritic cells similarly produce PGE₂ *in vivo*.

114 Here, we demonstrated *ex vivo* that macrophages and dendritic cells produce PGE₂ in
115 response to *L. monocytogenes* infection. Importantly, induction of PGE₂ *ex vivo* was partially
116 dependent on cytosolic access, as infection of bone marrow-derived macrophages or dendritic
117 cells with vacuole-constrained *L. monocytogenes* led to reduced PGE₂ compared to wild-type
118 strains. In contrast, *in vivo* PGE₂ production requires cytosolic access, as infection with LLO-
119 deficient *L. monocytogenes* led to a complete lack of PGE₂ induction, similar to mock-
120 immunized levels. Lyz2⁺ and CD11c⁺ cells contribute to PGE₂ production *in vivo*, as deletion of
121 COX-2 selectively in these subsets led to reduced splenic PGE₂ levels. However, these subsets

122 are not solely responsible for production as a small amount of PGE₂ remains and this remaining
123 PGE₂ is sufficient to facilitate optimal T-cell priming. Use of phagocyte-depleting clodronate
124 treatment completely eliminated PGE₂ production to mock-immunized levels. Taken together,
125 this work identifies, for the first time, a cytosolic-dependent pathway critical for inducing
126 immunity to *L. monocytogenes*. We show that phagocytes, particularly macrophages and
127 dendritic cells, produce PGE₂ in a cytosol-dependent manner.

128 **Results**

129 **Unprimed macrophages and dendritic cells upregulate PGE₂-synthesizing enzymes in** 130 **response to cytosolic *L. monocytogenes***

131 We previously demonstrated that immunization of mice with *L. monocytogenes* induces
132 production of PGE₂, starting at four hours post infection and peaking at twelve hours, and that
133 this transient PGE₂ production is necessary for optimal T-cell priming[14]. During infection, *L.*
134 *monocytogenes* infects multiple phagocytic cell populations in the spleen, the majority of which
135 are macrophage and dendritic cell subsets[20]. Initially, *L. monocytogenes* localizes to multiple
136 macrophage subsets[20] and by twelve hours after infection, CD11c⁺ dendritic cells comprise the
137 largest subset of *L. monocytogenes* infected cells[20]. We hypothesized that macrophages and
138 dendritic cells were the subsets producing PGE₂ due these cells being the predominantly infected
139 cell subsets at these early timepoints post immunization. To determine if *L. monocytogenes*
140 infection induces the genes necessary for PGE₂ production, we first measured expression of
141 *Pla2g4a* mRNA (encoding cPLA2), a phospholipase that releases arachidonic acid from the cell
142 membrane[15], in bone marrow derived macrophages (BMDMs) and bone marrow derived
143 dendritic cells (BMDCs). BMDMs and BMDCs were infected with *L. monocytogenes* and
144 mRNA was harvested six hours later. We found that cPLA2 expression did not change during *L.*
145 *monocytogenes* infection (S1 Fig). This result was not surprising, as much of cPLA2 activity is
146 modulated by calcium influx and MAPK phosphorylation rather than transcriptional
147 changes[22]. We next measured mRNA expression of *Ptgs2* (encoding COX-2) and *Ptges*
148 (encoding mPGES-1), encoding enzymes involved in the next steps of PGE₂ synthesis[16,19]. In
149 both BMDMs and BMDCs, infection with wild-type *L. monocytogenes* led to an increase in
150 *Ptgs2* expression and, to a lower extent, *Ptges*, suggesting that macrophages and dendritic cells

151 could be capable of synthesizing PGE₂ (Fig 1A-B). Given that PGE₂ is necessary for optimal T-
152 cell priming and that immunizing mice with a strain of *L. monocytogenes* that cannot access the
153 cytosol leads to reduced T-cell effector function[9,10], we hypothesized that impaired T-cell
154 responses to vacuole constrained bacteria may be due to reduced expression of PGE₂-
155 synthesizing enzymes and ultimately decreased production of PGE₂. To test this hypothesis, we
156 infected BMDMs and BMDCs with a vacuole-constrained strain of *L. monocytogenes* (Δhly , a
157 mutant lacking the pore-forming protein LLO) and assessed expression of *Ptges* and *Ptgs2*
158 mRNA. Consistent with this hypothesis, infection with this strain led to reduced *Ptgs2*
159 expression in BMDMs and BMDCs, suggesting that cytosolic access is required for optimal
160 expression of *Ptgs2* (Fig 1A). Interestingly, infection with Δhly *L. monocytogenes* led to similar
161 levels of *Ptges* expression in both BMDMs and BMDCs (Fig 1B). Taken together, these results
162 suggest that cytosolic access increases *Ptgs2* expression in BMDMs and BMDCs, whereas *Ptges*
163 expression is induced independently of cytosolic access. Additionally, as controls we assessed
164 expression of *Ifnb1* (encoding IFN- β) and *Il1b* (encoding IL-1 β) in BMDMs and BMDCs. As
165 expected, *Ifnb1* was expressed only during infection with cytosolic, wild-type *L. monocytogenes*
166 in both cell subsets (S1 Fig), where *Il1b* was induced by TLR signaling during infection with
167 both wild-type and Δhly *L. monocytogenes* infection (S1 Fig).

168

169 Given that *Ptgs2* expression was higher during infection with wild-type compared to Δhly *L.*
170 *monocytogenes*, we next assessed whether the increased transcript in wild-type infection led to
171 increased COX-2 protein expression. To assess the role of cytosolic access on COX-2 protein
172 levels, we infected BMDMs or BMDCs with wild-type or Δhly *L. monocytogenes* and assessed
173 COX-2 protein expression six hours later by western blot. In BMDMs, interestingly, infection

174 with either strain of *L. monocytogenes* led to increased COX-2 protein expression (Fig 1C). In
175 BMDCs, alternatively, Δhly *L. monocytogenes* induced lower levels of COX-2 protein (Fig 1C).
176 This suggests that cytosolic access is required for robust induction of COX-2 protein expression
177 in BMDCs.

178
179 Infection of BMDMs and BMDCs with wild-type *L. monocytogenes* led to expression of the
180 genes necessary for PGE₂ production (Fig 1A-C). To assess whether these cells could utilize
181 these enzymes to produce PGE₂, we assessed PGE₂ production in culture supernatant by mass
182 spectrometry. Surprisingly, supernatant from both BMDMs and BMDCs had no detectable PGE₂
183 compared to PBS-treated controls, both during infection with wild-type or Δhly *L.*
184 *monocytogenes* (Fig 1D). This suggests that either enzyme expression was not high enough to
185 induce detectable PGE₂, or there may be additional post transcriptional modifications required
186 for enzyme activity. Analysis of PGE₂ from BMDMs or BMDCs deficient in COX-2 had no
187 detectable PGE₂, as expected (Fig 1D).

188
189 **Primed BMDMs and BMDMs produce PGE₂ during cytosolic *L. monocytogenes* infection**
190 The lack of PGE₂ produced by BMDMs and BMDCs in response to *L. monocytogenes* infection
191 was surprising given the upregulation of *Ptgs2* and *Ptges* transcript. Other innate pathways, such
192 as the inflammasome, require a priming step in order to induce optimal activation. We
193 hypothesized that macrophages may similarly require additional stimulation in order to produce
194 PGE₂. To test this hypothesis, we treated BMDMs and BMDCs overnight with the TLR2 agonist
195 PAM3CSK4 (PAM) before infection with wild-type and Δhly *L. monocytogenes* and again
196 analyzed transcript expression. PAM alone induced a small amount of expression of *Ptgs2*

197 expression in both BMDMs and BMDCs (Fig 1A). Infection with wild-type *L. monocytogenes*
198 led to a significant increase in expression that was less robust in Δhly *L. monocytogenes*-infected
199 cells, similar to the effect seen in unprimed cells (Fig 1A). *Ptges* expression, alternatively, had a
200 larger increase in transcript expression during PAM-priming, both during wild-type and Δhly *L.*
201 *monocytogenes* infection of BMDMs and BMDCs (Fig 1B). Furthermore, PAM treatment alone
202 induced expression of *Ptges* similar to that induced during infection in BMDMs (Fig 1B). Taken
203 together, these data suggest that cytosolic access accentuates expression of *Ptgs2*, where TLR
204 signaling alone is sufficient to induce *Ptges* expression. We also assessed expression of *Pla2g4a*
205 in TLR-primed BMDMs and BMDCs and, similar to unprimed cells, saw no changes in
206 expression (S1 Fig). Additionally, *Ifnb1* transcript was again induced during cytosolic infection,
207 where *Il1b* expression was induced during PAM-treatment alone, as well as during infection with
208 wild-type or Δhly *L. monocytogenes* (S1 Fig).

209
210 As *Ptgs2* expression was also dependent on cytosolic access in primed BMDMs and BMDCs, we
211 next assessed expression of COX-2 protein in primed cells infected with wild-type or Δhly *L.*
212 *monocytogenes* by western blot. Similar to unprimed cells, BMDMs had similar levels of COX-2
213 protein during infection with wild-type or Δhly *L. monocytogenes* (Fig 1C). In BMDCs,
214 alternatively, COX-2 protein expression was reduced during infection with Δhly *L.*
215 *monocytogenes* compared to wild-type infection (Fig 1C), again suggesting that COX-2 protein
216 expression in BMDCs is potentiated by cytosolic access.

217
218 We hypothesized that priming BMDMs and BMDCs with PAM would stimulate the cells to
219 produce PGE₂ during infection with wild-type *L. monocytogenes*. To test this hypothesis, we

220 assessed production of PGE₂ in the supernatant of primed BMDMs and BMDCs by mass
221 spectrometry. BMDMs and BMDCs were treated overnight with PAM before infection with
222 wild-type and Δhly *L. monocytogenes*. Six hours post-infection, cell supernatant was assessed for
223 PGE₂. In contrast to unprimed BMDM and BMDCs, wild-type infection of primed cells led to a
224 significant increase in PGE₂ production compared to PBS-treated controls (Fig 1D). Previous
225 data showed *L. monocytogenes*-stimulated PGE₂ production in peritoneal macrophages[21,23].
226 Our data suggest that priming BMDMs prior to infection induces the cells to behave more like
227 tissue resident macrophages in respect to PGE₂ production. Furthermore, the ability of BMDMs
228 to produce PGE₂ provides a tool to efficiently study PGE₂ synthesis in macrophages during
229 infection. Importantly, maximal PGE₂ production in primed BMDM and BMDCs was dependent
230 on cytosolic access, as infection with Δhly *L. monocytogenes* led to significantly reduced PGE₂
231 levels (Fig 1D). PAM-primed COX-2 deficient BMDMs and BMDCs again led to no PGE₂
232 production, solidifying the necessity of COX-2 activity in PGE₂ production (Fig 1D).

233
234 Additionally, we also sought to understand whether PGE₂ specifically was being induced, or if
235 there was a more broad increase eicosanoid production. To test the hypothesis that *L.*
236 *monocytogenes* induces production of other eicosanoids, we analyzed production of
237 prostaglandin D₂ (PGD₂), thromboxane B₂ (TXB₂), and leukotriene B₄ (LTB₄). However, we saw
238 no changes production of these eicosanoids by wild-type *L. monocytogenes* (S2 Fig). This
239 interesting observation suggests that macrophages and dendritic cells preferentially induce PGE₂
240 in response to infection with cytosolic *L. monocytogenes*.

241
242 **Cytosolic access is required for PGE₂ production *in vivo***

243 Production of PGE₂ by TLR-primed BMDMs and BMDCs *ex vivo* is potentiated by cytosolic
244 access. To assess whether *L. monocytogenes* induces PGE₂ in a cytosol-dependent manner *in*
245 *vivo*, we infected mice intravenously with wild-type and Δhly *L. monocytogenes* and assessed
246 PGE₂ levels in the spleen twelve hours post-infection, previously defined as the peak PGE₂
247 response to infection[14]. Wild-type *L. monocytogenes* led to an eight-fold increase in PGE₂ (Fig
248 2A). Infection with Δhly *L. monocytogenes* strikingly showed no increase in PGE₂ over mock-
249 immunized controls (Fig 2A). To ensure that the reduced PGE₂ production was not due to
250 differences in bacterial burdens, mice were infected at a dose of wild-type (10^5 bacteria) and
251 Δhly *L. monocytogenes* (10^7 bacteria) that led to comparable burdens (Fig 2B). This shows that
252 the absence of PGE₂ in Δhly *L. monocytogenes*-infected mice is not just due to reduced bacterial
253 burdens. Taken together, these data highlight that cytosolic access is necessary for *in vivo*
254 induction of PGE₂.

255

256 **CD11c⁺ and Lyz2⁺ cells produce PGE₂ during *L. monocytogenes* infection *in vivo***

257 Our data identified PGE₂ production by macrophages and dendritic cells *ex vivo* (Fig 1D).
258 Furthermore, previous groups have reported that macrophage and dendritic cell subsets are
259 heavily infected early during *in vivo* infection, a timepoint where we have previously detected
260 increases in splenic PGE₂[14,20]. From these data, we next hypothesized that macrophages
261 and/or dendritic cells were responsible for producing PGE₂ *in vivo* that is necessary for optimal
262 T-cell priming. To test this hypothesis, we generated mice deficient in COX-2 selectively in
263 CD11c⁺ cells or Lyz2⁺ cells using the cre/lox system. Mice containing *loxP* sites flanking the
264 COX-2-encoding gene (COX-2^{fl/fl}) were crossed with mice expressing the cre recombinase under
265 the CD11c or Lyz2 promoters. COX-2^{fl/fl} CD11c-cre and COX-2^{fl/fl} Lyz2-cre mice (subsequently

266 referred to as CD11c-cre and Lyz2-cre) were immunized with 10^7 CFU of a live-attenuated,
267 vaccine strain of *L. monocytogenes* (LADD *L. monocytogenes*) currently used in clinical trials as
268 a cancer therapy platform[24]. The LADD strain is deficient in two major virulence genes, *actA*
269 and *inlB*, that retains immunogenicity while making it safe for clinical use[24]. The vaccine
270 strain was used here to enable analysis of T-cell responses in floxed mice as discussed below and
271 induces similar levels of PGE₂[14]. Immunization of CD11c-cre and Lyz2-cre mice each showed
272 reduced levels of PGE₂ production, leading to only 60% of the PGE₂ induced during
273 immunization of control mice (Fig 3A). However, deletion of COX-2 in either CD11c⁺ or Lyz2⁺
274 cells did not abrogate production to the level of mice globally deficient in mPGES-1 (mPGES-1⁻
275 ⁻) (Fig 3A). This suggests that CD11c⁺ and Lyz2⁺ cells each contribute to PGE₂ production and
276 that deletion of COX-2 in either is not sufficient to completely prevent PGE₂ production. We
277 also assessed PGE₂ levels in mice deficient in COX-2 selectively in T-cells and observed no
278 reduction of PGE₂ (S3 Fig). As T-cells are not known to be infected by *L. monocytogenes*, this is
279 consistent with our hypothesis suggesting PGE₂ production specifically from infected cell
280 subsets.

281
282 PGE₂ is critical for generating optimal T-cell responses in response to *L. monocytogenes*, as
283 immunization of mPGES-1-deficient mice or treatment of mice with a COX-2-specific
284 pharmacological inhibitor leads to impaired T-cell responses[14]. We next hypothesized that the
285 decreased PGE₂ production in the CD11c-cre or Lyz2-cre mice would be sufficient to similarly
286 impair T-cell responses. To test this hypothesis, we immunized mice with 10^7 LADD *L.*
287 *monocytogenes* expressing the model antigens B8R and OVA. Seven days after immunization,
288 splenocytes were isolated, stimulated with B8R or OVA, and production of IFN was assessed by

289 flow cytometry. Despite decreased PGE₂ production in these mice, T-cell responses were not
290 affected both in percent IFN⁺ as well as number of IFN⁺ T-cells per spleen (Fig 3B-C, S4 Fig)
291 Similarly, the number of antigen-specific T-cells measured by B8R tetramer was unchanged in
292 these mice compared to control mice (S4 Fig). This suggests that the PGE₂ remaining in these
293 mice was sufficient to prime productive T-cell responses. Due to its short *in vivo* half-life, PGE₂
294 asserts its effects locally[25]. It is possible that while global splenic PGE₂ levels are decreased,
295 the local concentrations of PGE₂ are sufficient to prime T-cell responses. Taken together, these
296 data suggest that although Lyz2⁺ and CD11c⁺ cells contribute to production of PGE₂ during *L.*
297 *monocytogenes* infection, PGE₂ production by these cells is not necessary, as T-cell responses
298 are not impacted by loss of PGE₂ production in either subset.

299

300 **Deletion of COX-2 in both Lyz2⁺ and CD11c⁺ cells further reduces splenic PGE₂ levels**

301 Our data showed that single deletions of COX-2 in CD11c⁺ or Lyz2⁺ cells reduced PGE₂, but not
302 to baseline values. We next hypothesized that PGE₂ production by either of these subsets
303 individually was sufficient for T-cell priming and that to observe impaired T-cell responses we
304 would have to eliminate PGE₂ production in both CD11c⁺ and Lyz2⁺ cells. To do this, we
305 crossed the COX-2^{fl/fl} CD11c-cre and COX-2^{fl/fl} Lyz2-cre mice, leading to mice with a COX-2
306 deletion in both cell subsets (COX-2^{fl/fl} CD11c-cre Lyz2-cre). We assessed the ability of these
307 mice to produce PGE₂ by mass spectrometry and found that PGE₂ was further reduced, with
308 about 40% the amount PGE₂ produced compared to immunized control mice (Fig 4A). This
309 suggests that CD11c⁺ and Lyz2⁺ cells produce the majority of PGE₂ during immunization with *L.*
310 *monocytogenes*.

311

312 Due to further reduced PGE₂ production in our mice deficient in COX-2 in both CD11c⁺ and
313 Lyz2⁺ cells, we next assessed T-cell responses in these mice. Mice again were immunized with
314 10⁷ vaccine strain of *L. monocytogenes* expressing the model antigens B8R and OVA and
315 assessed for IFN production seven days later. Despite diminished PGE₂ production, T-cell
316 responses were again not affected, both in percent and number (Fig 4B-C, S5 Fig) Similarly,
317 antigen-specific T-cells measured by B8R tetramer were also unchanged compared to wild-type
318 controls (S5 Fig). This suggest that even the small amount of PGE₂ produced locally is sufficient
319 to drive T-cell responses.

320

321 **Depletion of phagocytes eliminates PGE₂ production *in vivo***

322 Our *ex vivo* data highlighted the capability of BMDMs and BMDCs to produce PGE₂ in response
323 to cytosolic *L. monocytogenes*. However, deletion of COX-2 in Lyz2⁺ and CD11c⁺ cells did not
324 completely abrogate PGE₂ production *in vivo*. These data led us to hypothesize that other
325 phagocytic cell subsets not effectively targeted by these cre-drivers may be producing the
326 residual PGE₂, such as marginal zone macrophages (MZMs), metallophilic macrophages, or
327 other CD11b⁺ cells more broadly[26,27]. To test this hypothesis, we utilized short-term
328 clodronate liposomes to rapidly deplete phagocyte populations in the spleen. Mice were depleted
329 with clodronate liposomes 24 hours prior to immunization with *L. monocytogenes*[28]. Twelve
330 hours post immunization, spleens were harvested and assessed for PGE₂ by mass spectrometry.
331 Additionally, splenocytes were assessed for CD11b⁺ and CD11c⁺ populations by flow cytometry
332 to confirm clodronate efficacy. Clodronate treatment led to significantly fewer CD11b⁺ cells and
333 a trend for decreased CD11c⁺ cells (S6 Fig). Treatment of mice with clodronate prior to infection
334 with *L. monocytogenes* completely eliminated PGE₂ production compared to infected control

335 mice (Fig 5A). Importantly, bacterial burdens were equivalent between clodronate and mock-
336 treated mice (Fig 5B). Pretreatment with a control empty liposome, encapsome, actually
337 increased PGE₂ production compared to infected control mice, potentially due to increased
338 bacterial burdens (Fig 5A-B). Taken together, these data demonstrate that phagocytic cell
339 populations are critical for PGE₂ production *in vivo* following *L. monocytogenes* immunization.
340
341 Loss of antigen presenting cells through clodronate treatment leads to impaired CD8⁺ T-cell
342 activation, making analysis of T-cell responses in this model not informative[29,30]. Given this,
343 we alternatively assessed the possibility that other phagocytic cells targeted by clodronate, but
344 not the Lyz2-cre, could contribute to PGE₂ production. Complete elimination of PGE₂ production
345 with clodronate treatment suggested that the residual PGE₂ in the CD11c-cre Lyz2-cre mice was
346 due to a phagocytic cell that was not effectively targeted in these mice. Previous data showed
347 that though the Lyz2-cre used in this study is highly efficient at deletion of *loxP* flanked genes in
348 some macrophage subsets, it is only minimally successful at deleting genes of interest in other
349 subsets, such as MZMs[26]. MZMs, characterized by expression of MARCO, are heavily
350 infected early in *L. monocytogenes* infection[20]. We hypothesized that the residual PGE₂ we
351 detected in our double CD11c-cre and Lyz2-cre mice may be due to inefficient deletion in
352 macrophage subsets such as these. To assess the role of MZMs in PGE₂ production, we assessed
353 expression of COX-2 by immunohistochemistry. Mice were immunized with 10⁷ vaccine strain
354 of *L. monocytogenes* and spleens were harvested three and ten hours later. Spleen cryosections
355 were then stained for *L. monocytogenes*, COX-2, and MARCO. Uninfected mice had COX-2
356 staining in the periarteriolar lymphoid sheath (PALS) with little expression in the marginal zone
357 (MZ) (Fig 5C,-D). As early as three hours post-immunization COX-2 staining was observed in

358 the MZ, with approximately 50% of COX-2 colocalizing with MARCO⁺ cells (Fig 5C-D).
359 Expression of COX-2 in the MZ was maintained at 10hpi, again showing approximately 50%
360 colocalization with MARCO (Fig 5C-D). Furthermore, *L. monocytogenes* colocalized with
361 COX-2 and MARCO expressing cells, suggesting that infected MZMs may be producing PGE₂
362 (Fig 5D). Expression of COX-2 suggests that MZMs, or other non-CD11c/Lyz2 expressing
363 phagocytes within the marginal zone, could be capable of producing PGE₂ *in vivo* and may be
364 contributing to the PGE₂ remaining in the CD11c-cre Lyz2-cre mice. Taken together, our data
365 suggest that multiple myeloid derived subsets can contribute to PGE₂ production, including
366 Lyz2⁺ cells, CD11c⁺ cells, and possibly MZMs. Complete reductions in PGE₂ by depletion of
367 phagocytic cells such as these with clodronate treatment is consistent with our data showing that
368 PGE₂ is produced from cells infected with cytosolic *L. monocytogenes*.

369 **Discussion**

370 Cytosolic access is required to effectively generate cell-mediated immunity to *L.*
371 *monocytogenes*[8–10]. Decades of work has focused on understanding the cytosol-dependent
372 processes necessary for T-cell priming, a topic that has gained interest recently due to use of *L.*
373 *monocytogenes* as a cancer immunotherapy platform. Our data suggest that one reason cytosolic
374 access is important is to facilitate phagocyte production of PGE₂, an eicosanoid required to
375 generate optimal CD8⁺ T-cell responses[14]. We showed that PGE₂ is produced by BMDMs and
376 BMDCs *ex vivo*. Importantly, this pathway requires cytosolic access, as vacuole-constrained *L.*
377 *monocytogenes* induce lower production of PGE₂. Furthermore, infection of mice with a vacuole-
378 constrained *L. monocytogenes* strain led to no increase of PGE₂ over mock immunized controls.
379 Lastly, we showed that Lyz2⁺ and CD11c⁺ cells contribute to PGE₂ production *in vivo* as deletion
380 of COX-2 in these subsets led to decreased PGE₂ levels, however other clodronate sensitive
381 phagocyte populations also contribute to PGE₂ production following *L. monocytogenes*
382 immunization. We demonstrate the first-known innate pathway critical for CD8⁺ T-cell responses
383 that requires cytosolic access by *L. monocytogenes*. This work leads to many new questions
384 including how cytosolic *L. monocytogenes* activates this pathway, how immune cells
385 discriminate which eicosanoid to produce in response to infection, how even small
386 concentrations of PGE₂ still lead to productive PGE₂ responses, and how PGE₂ facilitates
387 optimal T-cell priming.

388 One intriguing hypothesis is that PGE₂ synthesis during *L. monocytogenes* infection is
389 driven by an innate cytosolic sensor. *L. monocytogenes* elicits a number of innate pathways that
390 could contribute to differential activation of the PGE₂-synthesis pathway. One possibility is that
391 induction of type I IFN influences PGE₂ production. Type I IFN can be induced cytosolically by

392 *L. monocytogenes* through recognition of cyclic diadenosine monophosphate (c-di-AMP). Upon
393 entry into the cytosol, *L. monocytogenes* secretes c-di-AMP through multidrug resistance
394 transporters[31,32] where it is recognized by either the reductase controlling NF- κ B
395 (RECON)[33] or stimulator of IFN genes (STING)[34,35]. STING activation leads to type I
396 interferon induction[34,35], and was originally hypothesized to be critical for T-cell responses.
397 Paradoxically, however, type I IFN inhibits cell-mediated immunity to *L. monocytogenes*[12].
398 Interestingly, there has been well documented crosstalk between the PGE₂ and type I IFN
399 pathways during infections with other pathogens such as influenza and *M. tuberculosis*[36,37].
400 In the context of influenza, Coulombe et al. showed that infection led to upregulation of PGE₂
401 and a subsequent decrease in type I IFN[36]. In contrast to *L. monocytogenes*, type I IFN is
402 important in generating cell-mediated immune responses to influenza. Accordingly, diminished
403 type I IFN due to increased PGE₂ reduces both acute and protective immunity during influenza
404 infection. On the other hand, Mayer-Barber et al. recently showed that inhibition of type I IFN
405 during *M. tuberculosis* infection led to an increased level of PGE₂ in an IL-1-dependent
406 manner[37]. This correlated with better bacterial control. Due to crosstalk between these two
407 pathways, it seems possible that recognition of c-di-AMP and subsequently upregulation of type
408 I IFN may also be playing a role in PGE₂ production during *L. monocytogenes* immunization.
409 Analysis of PGE₂ levels in mice deficient in STING or the type I IFN receptor (IFNAR) could
410 advance understanding of the link between these two pathways. Alternatively, should type I IFN
411 influence PGE₂ production, use of *L. monocytogenes* strains that have reduced secretion of c-di-
412 AMP and subsequently less type I IFN could be an avenue of further research for
413 immunotherapeutic platforms.

414 Another cytosolic pathway that may influence PGE₂ levels during *L. monocytogenes*
415 infection is the inflammasome. Inflammasomes are multiprotein complexes that recognize a wide
416 range of pathogen associated molecular patterns[38–40]. Wild-type *L. monocytogenes* infection
417 leads to a small amount of inflammasome activation, largely through the absent in melanoma 2
418 (AIM2) inflammasome[41]. The AIM2 inflammasome recognizes cytosolic DNA that is released
419 during bacteriolysis within the cytosol[41–43]. Originally, inflammasomes such as AIM2 were
420 known to have two major downstream effects, the release of proinflammatory cytokines IL1 β /IL-
421 18 and the induction of a lytic form of cell death, pyroptosis, characterized by formation of
422 membrane pores by the protein Gasdermin D[44–46]. Seminal work by von Moltke et al.
423 introduced a new downstream effect, the activation of an eicosanoid storm, including PGE₂[23].
424 This work, as well as supporting recent work, showed elevated levels of PGE₂ after
425 inflammasome activation[23,47]. One possible hypothesis stemming from this work is that
426 induction of membrane pores during pyroptosis leads to calcium influx, activating cPLA2 and
427 releasing arachidonic acid from the membrane. This model would suggest that use of mice
428 deficient in caspase-1 or Gasdermin D would lead to lower levels of PGE₂ production.
429 Alternatively, infection of *L. monocytogenes* strains that differentially activate inflammasomes
430 would lead to different PGE₂ production. The role of inflammasomes as well as type I IFN are
431 intriguing avenues to understand signaling pathways driving PGE₂ production during *L.*
432 *monocytogenes* infection.

433 It is also possible that production of PGE₂ by *L. monocytogenes* is independent of known
434 cytosolic pathways. Identification of other unknown sensors could be accomplished by assessing
435 PGE₂ levels in response to different *L. monocytogenes* mutants. Mutant strains of *L.*
436 *monocytogenes* that differentially induce PGE₂ could provide insight as to the cytosolic sensors

437 involved. One additional hypothesis is that PGE₂-production is independent of a cytosolic sensor
438 completely and instead is driven by LLO-mediated pore formation. Though LLO is tightly
439 regulated transcriptionally, translationally, and posttranslationally to be most active in the
440 vacuole, a small amount of LLO may remain active in the cytosol of cells[48–50]. Perhaps, this
441 small amount of LLO induces pore formation in the cell membrane and allows calcium influx,
442 subsequently activating cPLA2. Use of strains that further restrict LLO production in the cytosol,
443 such as new strains that excise *hly* once *L. monocytogenes* has entered the cytosol[51], could
444 help assess the role of LLO-mediated pores on PGE₂ production.

445 In addition, our data show an interesting phenotype where BMDCs and PAM-primed
446 BMDMs selectively produce PGE₂ in response to *L. monocytogenes* infection rather than a
447 global increase in eicosanoid production. Analysis of eicosanoid milieu in cell supernatant show
448 an increase in PGE₂ production during wild-type *L. monocytogenes* infection, but little to no
449 changes in other eicosanoids such as PGD₂, TXB₂, or LTB₄. This raises the question of how a
450 cell discriminates which eicosanoid is produced in response to different stimuli. The eicosanoid
451 produced in different conditions is dependent on terminal synthases[19]. Therefore, the
452 expression and activity of these synthases determine the resulting eicosanoid milieu. Multiple
453 factors impact expression of different synthases including cytokines, hormones, and microbial
454 products[52]. For example, expression of mPGES-1 can be induced by LPS and prostaglandin D₂
455 synthases, though less well understood, can be upregulated by glucocorticoids[53–55]. Use of *L.*
456 *monocytogenes* strains that differentially activate cytokines or are deficient in different microbial
457 PAMPs could be informative as to which signal specifically leads to enhanced levels of mPGES-
458 1 transcript. In addition, activity of each synthase also may dictate which eicosanoids are
459 produced[52]. Terminal synthase activity can be modulated by posttranslational modification

460 (such as phosphorylation) as well as presence of cofactors (such as ATP and glutathione)[52].
461 Depletion of essential cofactors during metabolic or oxidative stress could influence the induced
462 inflammatory milieu[52]. The post transcriptional regulation highlights the necessity of assessing
463 endpoint eicosanoid production rather than simply transcript or protein levels, as these other
464 factors influencing activity can alter which eicosanoids ultimately are produced. This is
465 particularly true in our data, as despite seeing upregulation of mPGES-1 transcript during
466 infection of unprimed BMDMs and BMDCs, we failed to see PGE₂ production. This suggests
467 that perhaps some additional modification is necessary to induce mPGES-1 activity during *L.*
468 *monocytogenes* infection.

469 Another pressing question generated from this work is how productive T-cell responses
470 were induced in mice deficient in COX-2 in both CD11c⁺ and Lyz2⁺ cells despite reduced PGE₂
471 levels. Here, we show that these mice produce substantially reduced PGE₂, yet still induce wild-
472 type CD8⁺ T-cell responses. One hypothesis that we explored in this work is that other cell
473 subsets not efficiently targeted by our cre/lox model were still producing PGE₂. Certain cell
474 subsets such as MZMs do not have effective gene deletion using the Lyz2⁺ promoter to drive cre
475 recombinase expression[26]. For this reason, we hypothesized that subsets such as these may still
476 be producing sufficient levels of PGE₂ to drive T-cell responses. One way to assess the role of
477 MARCO⁺ MZMs is use of a new cre recombinase-driving promoter, SIGN-R1, developed by
478 Pirgova et al[27]. SIGN-R1 is a lectin binding receptor expressed on MZMs and drives more
479 efficient deletion of genes by the cre/lox system[27]. Generation of triple COX-2 knockout mice
480 that express the SIGN-R1-cre in combination with our reported Lyz2-cre CD11c-cre model
481 could be informative about the role of MZMs in production of PGE₂. Though we show that

482 Lyz2⁺ and CD11c⁺ cells contribute to PGE₂, analysis of MZMs and other myeloid cells will
483 further understanding of PGE₂ production.

484 The lack of diminished cell-mediated immunity could also be due to local acting effects
485 of PGE₂. It is possible that even if PGE₂ levels are below detection at a whole spleen level,
486 certain cells are able to produce PGE₂ locally in sufficient concentration to drive T-cell
487 responses. More sensitive measures of PGE₂, such as quantitative mass spectrometry imaging
488 recently developed, would be required to analyze local responses such as these[56]. These novel
489 techniques enable analysis of location of PGE₂ and other eicosanoids within a spleen and could
490 detect lower concentrations[56]. Similarly, the sensitivity of the receptor PGE₂ is acting upon
491 during *L. monocytogenes* infection could influence how much PGE₂ is necessary for inducing a
492 response. PGE₂ binds primarily to four receptors, EP1-4[57]. EP3 and EP4 are higher affinity
493 receptors (kD ~1nM compared to 10-15nM for EP1/2)[57,58]. Should the higher affinity
494 receptors be identified as the important receptors for influencing immunity during *L.*
495 *monocytogenes* infection, even lower concentrations of PGE₂ still induced in our Lyz2-cre
496 CD11c-cre model may be sufficient for cell-mediated responses. Further analysis as to relevant
497 receptors and which cells they are expressed on could help elucidate these details.

498 Lastly, how PGE₂ facilitates T-cell responses in the context of *L. monocytogenes*
499 immunization remains unknown. In innate immune cells, PGE₂ influences expression of co-
500 stimulatory and activation markers. PGE₂ signaling in dendritic cells upregulates the co-
501 stimulatory molecules OX40L and 4-1BBL[59], thereby promoting T-cell proliferation.
502 Similarly, PGE₂ signaling in macrophages leads to polarization towards a more inflammatory
503 M1 phenotype[60] and aids in activation[61]. Furthermore, PGE₂ promotes migration of innate
504 cell subsets, leading to enhanced migration towards CCL21[62,63] and MCP-1[64,65]. These

505 proinflammatory functions suggest that PGE₂ may be acting to enhance immunity through its
506 local effects on innate immune cells. PGE₂ may also be influencing immunity more directly on
507 T-cell subsets, such as through polarization of T-cells towards a Th1 phenotype[66].
508 Additionally, PGE₂ leads to higher expression of OX-40L, OX-40, and CD70 directly on T-cells,
509 promoting T-cell interactions and sustaining immune responses[59]. In order to more fully
510 understand how PGE₂ facilitates T-cell responses to *L. monocytogenes*, a comprehensive analysis
511 of these effects on both T-cells and innate immune cells is required.

512 We and others have shown that innate immune responses substantially influence cell-
513 mediated immune responses, particularly the inflammatory milieu induced during infection.
514 Here, we present evidence that one pathway critical for immunity, induction of PGE₂, is
515 dependent on access to the cytosol. Furthermore, we show that PGE₂ is produced by
516 macrophages and dendritic cells. These data provide new insight as to how CD8⁺ T-cells are
517 primed as well as suggest analysis and modulation of eicosanoid levels, particularly PGE₂ levels,
518 may be informative to improve the use of *L. monocytogenes*-based immunotherapeutic
519 platforms.

520

521 **Materials and Methods**

522 **Ethics statement:** This work was carried out in strict accordance with the recommendations in
523 the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All
524 protocols were reviewed and approved by the University of Wisconsin-Madison Institutional
525 Animal Care and Use Committee.

526

527 **Bacterial strains:** The *Listeria monocytogenes* strains used in this study were all in the 10403s
528 background. The attenuated (LADD) strain used in the analysis of T-cell responses was in the
529 $\Delta actA\Delta inlB$ background as previously described and engineered to express full length OVA and
530 the B8R₂₀₋₂₇ epitope[24]. OVA and B8R₂₀₋₂₇ were constructed as a fusion protein under the
531 control of the *actA* promoter with the secretion signal of the amino terminal 300bp of the ActA
532 gene[13]. This fusion protein was integrated into the site-specific pPL2e vector as previously
533 described[13].

534

535 **Mouse strains:** Six- to eight-week-old C57BL/6 male and female mice were obtained from the
536 NCI and Charles River NCI facility. *Ptgs2*^{-/-} (COX-2^{-/-}) mice were obtained from Jackson
537 Laboratory and maintained as heterozygote breeding pairs. *Ptges*^{-/-} (mPGES1^{-/-}) mice lacking
538 microsomal PGE synthase have been previously described[67–69]. In order to generate cell-type
539 specific COX-2 knockout mice, COX-2^{fl/fl} mice (stock number 030785) were obtained from
540 Jackson Laboratory and crossed with Lyz2-cre (stock number 004781), CD11c-cre (stock
541 number 008068), or CD4-cre expressing mice (stock number 022071), all also obtained from
542 Jackson Laboratory. Double Lyz2-cre and CD11c-cre expressing mice were generated by

543 crossing COX-2^{fl/fl} Lyz2-cre mice with COX-2^{fl/fl} CD11c-cre mice. Genotypes were confirmed
544 by PCR using the primer pairs in Table 1.

545 **Table 1. Genotyping primers**

Mouse genotype	Forward (5'-3')	Reverse (5'-3')
COX-2 ^{fl/fl}	AAT TAC TGC TGA AGC CCA CC	CTT CCC AGC TTT TGT AAC CAT
CD4-cre	GAACC TGATG GACAT GTTCA GG TTACG TCCAT CGTGG ACAGC (internal control)	AGTGC GTTCG AACGC TAGAG CCTGT TGGGC TGGGT GTTAG CCTTA (internal control)
CD11c-cre	ACT TGG CAG CTG TCT CCA AG CAA ATG TTG CTT GTC TGG TG (internal control)	GCG AAC ATC TTC AGG TTC TG GTC AGT CGA GTG CAC AGT TT (internal control)
Lyz2-cre	CCC AGA AAT GCC AGA TTA CG	CTT GGG CTG CCA GAA TTT CTC

546

547 **BMDM and BMDC generation and infection:** Bone marrow-derived macrophages and
548 dendritic cells were made using six- to eight-week-old *Ptgs2*^{-/-} (COX-2^{-/-}) or C57BL/6 mice as
549 previously described[13,70]. Briefly, bone marrow was harvested and macrophages were
550 cultured in the presence of M-CSF from transfected 3T3 cell supernatant for six days with a
551 supplement of M-CSF at day three and frozen down for storage. Dendritic cells were cultured in
552 the presence of 20ng/ml recombinant GM-CSF (BD Biosciences, San Jose, CA) for 7 days with
553 a supplement of 20ng/mL GM-CSF every third day. For infection, BMDMs or BMDCs were
554 plated at 1x10⁶ cells/well in a 12 well dish overnight +/- 100ng/mL PAM3CSK4. The following
555 morning, cells were infected with indicated strains of *L. monocytogenes* or PBS control at an
556 MOI of 10. Thirty minutes later, supernatant was removed and replaced with medium containing
557 50µg/mL gentamycin to remove extracellular bacteria. Six hours post infection, cells were

558 harvested for western blot or qRT PCR and supernatant was harvested for eicosanoid analysis as
 559 described below.

560

561 **qRT PCR:** RNA was isolated from BMDMs or BMDCs using the RNAqueous-Micro Total
 562 RNA Isolation Kit (Invitrogen), and DNase treated with Turbo DNase (Invitrogen) according to
 563 manufacturer's instructions. 500ng total RNA was reverse transcribed in 10µL reactions using
 564 the iScript cDNA Synthesis Kit (BioRad) according to manufacturer's instructions and cDNA
 565 was diluted 10-fold using molecular grade water (Invitrogen). 2.5µL diluted cDNA was used as
 566 template in a 10µL qRT-PCR reaction performed in duplicate using gene-specific primers and
 567 Kapa SYBR Green Universal qPCR mix (KAPA Biosystems) according to manufacturer's
 568 instructions using a BioRad CFX Connect Real-Time PCR System. The sequences of gene-
 569 specific primers are shown in Table 2. Data was analyzed using Excel and all RNA abundances
 570 were calculated by using a standard curve of synthesized template (Integrated DNA
 571 Technologies, G-Blocks) and are normalized to *ActB* (β -actin).

572 **Table 2. qRT PCR primers**

Gene	Forward (5'-3')	Reverse (5'-3')
<i>ActB</i>	AAT TAC TGC TGA AGC CCA CC	CTT CCC AGC TTT TGT AAC CAT
<i>Ptgs2</i>	GAACC TGATG GACAT GTTCA GG TTACG TCCAT CGTGG ACAGC (internal control)	AGTGC GTTCG AACGC TAGAG CCTGT TGGGC TGGGT GTTAG CCTTA (internal control)
<i>Ptges</i>	ACT TGG CAG CTG TCT CCA AG CAA ATG TTG CTT GTC TGG TG (internal control)	GCG AAC ATC TTC AGG TTC TG GTC AGT CGA GTG CAC AGT TT (internal control)
<i>Pla2g4a</i>	CCC AGA AAT GCC AGA TTA CG	CTT GGG CTG CCA GAA TTT CTC
<i>Ifnb1</i>	GCACTGGGTGGAATGAGACTATTG	TTCTGAGGCATCAACTGACAGGTC
<i>Il1b</i>	GACCTGTTCTTTGAAGTTGACGG	TGTCGTTGCTTGGTTCTCCTTG

--	--	--

573

574 **Western blots:** BMDMs or BMDCs were harvested and protein was extracted using the Pierce
575 SDS-PAGE Sample Prep Kit (Thermo) according to the manufacturer's instructions. Total
576 protein content was measured by the Pierce BCA Protein Assay Kit (Thermo) and equivalent
577 protein levels were loaded into an polyacrylamide gel (BioRad). Samples were transferred onto a
578 nitrocellulose membrane using a semi-dry transfer apparatus before blocking with a 5% skim
579 milk solution for thirty minutes at room temperature. After washing 3x with PBS-T, the
580 membrane was incubated overnight at 4°C with the primary antibodies anti-COX-2 (1:200,
581 Cayman Chemical) and anti- β -actin loading control (1:1000, ThermoFisher) in a 5% bovine
582 serum albumin solution. The following day samples were washed with PBS-T before being
583 incubated with secondary antibodies (anti-rabbit 800 at 1:10,000, anti-mouse 680 at 1:5,000).
584 Samples were imaged on a LiCor imager and analyzed via ImageStudio. Sample signal was
585 normalized to β -actin and relative abundance was compared to wild-type *L. monocytogenes*.

586

587 ***In vivo* immunizations and pharmacological treatments:** *L. monocytogenes* of the wild-type,
588 attenuated (LADD), or *Δhly* background were grown overnight in brain heart infusion media at
589 30C. The bacteria were back diluted 1:5 and allowed to grow to log phase (OD0.4-0.6, ~1-1.5
590 hours) at 37C, with aeration, prior to infection. Bacteria were diluted in PBS and mice were
591 infected with 200 μ L at the indicated doses intravenously. For bacterial burden analysis, mice
592 were sacrificed at 12hpi and livers were homogenized in 0.1% Nonidet P-40 in PBS and plated
593 on Luria-Bertani plates. For splenic macrophage depletion, 200 μ L clodronate, PBS control, or
594 endosome lipid control (Encapsula Nano Sciences) were given intravenously 24 hours prior to
595 bacterial infection according to the manufacturer's instructions. Depletion efficacy was

596 confirmed by assessing abundance of splenic CD11b⁺ cells (clone M1/70) and CD11c⁺ cells
597 (clone N418) by flow cytometry. Celecoxib (Cayman Chemical) was milled into standard mouse
598 chow (Envigo) at 100mg/kg and fed ad lib for 48 hours before and after immunization[14,71].

599

600 **Eicosanoid measurement:** For *in vivo* eicosanoid extractions, spleens from mice were harvested
601 at twelve hours post immunization and flash frozen in tubes containing 50ng deuterated PGE₂
602 standard (Cayman Chemical) in 5μL methanol and stored overnight at -80C. For *ex vivo*
603 extractions, 1mL of supernatant was flash frozen in tubes similarly containing 50ng deuterated
604 PGE₂ standard in 5μL methanol. The following day, two mL of ice cold methanol were added to
605 the tissue culture supernatant or spleens. Spleens were homogenized in glass homogenizers.
606 Samples then were incubated at 4C for 30 minutes. Next, cellular debris was removed by
607 centrifugation and samples were concentrated to 1mL volume before being acidified with pH 3.5
608 water and loaded onto conditioned solid phase C18 cartridges. Samples were washed with
609 hexanes before eluting using methyl formate followed by methanol. Samples were concentrated
610 using a steady stream of nitrogen gas and suspended into 55:45:0.1 MeOH:H₂O:acetic acid and
611 analyzed on an HPLC coupled to a mass spectrometer (Q Exactive; Thermo Scientific) using a
612 C18 Acquity BEH column (100mm x 2.1 mm x 1.7μm) operated in negative ionization mode.
613 Samples were eluted with a mobile phase 55:45:0.1 MeOH:H₂O:acetic acid shifted to 98:2:0.1
614 over 20 minutes. Mass-to-charge ratios included were between 100 and 800 and compared to
615 standards (Cayman Chemical) by analysis via MAVEN.

616

617 **T-cell analysis:** Mice were sacrificed seven days after immunization and splenocytes were
618 isolated as previously described[4]. In brief, red blood cells were lysed using ACK buffer and

619 then splenocytes were counted using a Z1 Coulter counter. For tetramer analysis, splenocytes
620 were immediately blocked for Fc (Tonbo Bioscience) and stained for B8R tetramer (AF488,
621 1:300, NIH Tetramer Facility, Atlanta, GA) followed by staining with anti-CD3 (PeCy7, 1:100,
622 clone 145-2C11) and anti-CD8 α (eFlour450, 1:200, clone 145-2C11). Cells were then stored
623 overnight at 4C in a 1:1 of IC Fixation Buffer (ThermoFisher Scientific) and FACS buffer. For
624 analysis of cytokine production, 1.7×10^6 cells were plated in a 96 well dish and incubated for
625 five hours in the presence of B8R₂₀₋₂₇ (TSYKFESV) or OVA₂₅₇₋₂₆₄ (SIINFEKL) peptides and
626 brefeldin A (eBioscience). Splenocytes were then subjected to FC block (Tonbo Bioscience) and
627 stained with anti-CD3 (FITC, 1:200, clone 145-2C11) and anti-CD8 α (eFlour450, 1:200, clone
628 53-6.7) before treatment with fixing and permeabilization buffers (eBioscience). Cells were then
629 further stained with anti-IFN γ (APC, 1:300, clone XMG1.2). Samples were acquired using the
630 LSRII flow cytometer (BD Biosciences, San Jose, CA) and analyzed with FlowJo software (Tree
631 Star, Ashland, OR).

632

633 **Cryosection preparation and immunofluorescence microscopy of infected spleens:** C57BL/6
634 mice were infected intravenously by tail vein injection of 10^7 LADD *L. monocytogenes* in 150 μ l
635 of PBS. Mice were sacrificed at 3 or 10 hpi and spleens harvested and snap frozen in OCT for
636 immunofluorescence microscopy as described previously[20]. Uninfected mice were used as
637 negative controls. Briefly, 5 μ m spleen cryosections were cut using a Leica CM1850 cryostat,
638 mounted on Superfrost Plus microscope slides (Thermo Fisher) and stored at -80°C until
639 use. Slides were fixed in 10% buffered formalin phosphate at RT for 5 minutes and sections,
640 washed in TBS and blocked with StartingBlock T20 Blocking buffer containing Fc blocker
641 (Thermo Scientific, 37543). Sections were incubated with unconjugated *L. monocytogenes*

642 monoclonal Ab (Invitrogen, MA1-20271), anti-MARCO polyclonal Goat IgG-Biotin (R&D
643 Systems, BAF2956), and FITC-conjugated COX2 polyclonal antibody (Cayman Chemical,
644 10010096) at 1/100-200 dilution at RT for 1-2h in dark humidified incubation chamber or
645 isotype control antibodies including Rabbit IgG-FITC (Invitrogen, 11-4614-80), Armenian
646 Hamster IgG-PE (Invitrogen, 13-4888-81) and Mouse IgG2a kappa (Invitrogen, 14-4724-81).
647 Biotinylated and unconjugated primary antibodies were detected by incubating with
648 Streptavidin-PE (Pharmingen, 534061) and Rat anti-mouse IgG2a antibody (Invitrogen, 17-
649 4210-80) respectively. Slides were preserved using ProLong Diamond Antifade mounting media
650 (Invitrogen, P36965) and clear nail polish to seal the edges. Slides were analyzed using an
651 Olympus IX51 fluorescence microscope equipped with LCPlanFL 20x/0.4 NA and UPlanFL
652 40x/1.3 oil objectives, an X-Cite 120 excitation unit (Exfo), FITC/PE/APC optimized filter sets
653 (Semrock), an Orca Flash 2.8 monochrome camera (Hamamatsu) and SlideBook software
654 (Intelligent Imaging Innovations) for hardware control and image acquisition. Images were
655 captured with both 20x an 40x objective with exposure times ranging from 200-400ms. Pseudo-
656 colored 3-channel RGB mages were imported into Imaris 9.6 (Bitplane) for smoothing, contrast
657 enhancement (linear contrast stretch), annotation and colocalization analysis.

658

659 **Statistical analysis:** Statistical analysis was performed by GraphPad Prism Software (La Jolla,
660 CA) and analyzed via Mann Whitney *U* test or one-way ANOVA with Bonferroni's correction as
661 indicated.

662

663 **Acknowledgments**

664 We would like to thank the NIH Tetramer Core Facility for provision of MHC-I B8R tetramers.

665 **References**

- 666 1. Rolhion N, Cossart P. How the study of *Listeria monocytogenes* has led to new concepts
667 in biology [Internet]. Vol. 12, *Future Microbiology*. Future Medicine Ltd.; 2017. p. 621–
668 38.
- 669 2. Le DT, Dubenksy TW, Brockstedt DG. Clinical development of *Listeria monocytogenes*-
670 based immunotherapies. *Semin Oncol*. 2012 Jun;39(3):311–22.
- 671 3. Corbin GA, Harty JT. Duration of Infection and Antigen Display Have Minimal
672 Influence on the Kinetics of the CD4 + T Cell Response to *Listeria monocytogenes*
673 Infection . *J Immunol*. 2004 Nov 1;173(9):5679–87.
- 674 4. Theisen E, Sauer JD. *Listeria monocytogenes*-Induced Cell Death Inhibits the Generation
675 of Cell-Mediated Immunity. Freitag NE, editor. *Infect Immun*. 2017 Jan;85(1):e00733-16.
- 676 5. Richer MJ, Nolz JC, Harty JT. Pathogen-specific inflammatory milieu tune the antigen
677 sensitivity of CD8(+) T cells by enhancing T cell receptor signaling. *Immunity*. 2013
678 Jan;38(1):140–52.
- 679 6. Portnoy DA, Jacks PS, Hinrichs DJ. Role of hemolysin for the intracellular growth of
680 *Listeria monocytogenes*. *J Exp Med*. 1988 Apr 1;167(4):1459–71.
- 681 7. Hamon MA, Ribet D, Stavru F, Cossart P. Listeriolysin O: the Swiss army knife of
682 *Listeria*. *Trends Microbiol*. 2012 Aug;20(8):360–8.
- 683 8. Michael Brunt L, Portnoy DA, Unanue ER. Presentation of *Listeria Monocytogenes* To
684 CD8+ T Cells Requires Secretion of Hemolysin and Intracellular Bacterial Growth'. *J*
685 *Immunol*. 2016;145(11).
- 686 9. Bahjat KS, Meyer-Morse N, Lemmens EE, Shugart JA, Dubensky TW, Brockstedt DG, et
687 al. Suppression of cell-mediated immunity following recognition of phagosome-confined

- 688 bacteria. PLoS Pathog. 2009 Sep;5(9):e1000568.
- 689 10. Berche P, Gaillard JL, Sansonetti PJ. Intracellular growth of *Listeria monocytogenes* as a
690 prerequisite for in vivo induction of T cell-mediated immunity. J Immunol. 1987 Apr
691 1;138(7):2266–71.
- 692 11. Auerbuch V, Brockstedt DG, Meyer-Morse N, O’Riordan M, Portnoy DA. Mice Lacking
693 the Type I Interferon Receptor are Resistant to *Listeria monocytogenes*. J Exp Med. 2004
694 Aug 16;200(4):527–33.
- 695 12. Archer KA, Durack J, Portnoy DA. STING-dependent type I IFN production inhibits cell-
696 mediated immunity to *Listeria monocytogenes*. PLoS Pathog. 2014 Jan;10(1):e1003861.
- 697 13. Sauer J, Pereyre S, Archer KA, Burke TP, Hanson B, Lauer P, et al. *Listeria*
698 *monocytogenes* engineered to activate the Nlr4 inflammasome are severely attenuated
699 and are poor inducers of protective immunity. Proc Natl Acad Sci U S A. 2011 Jul
700 26;108(30):12419–24.
- 701 14. Theisen E, McDougal C, Nakanishi M, Stevenson DM, Amador-Noguez D, Rosenberg
702 DW, et al. Cyclooxygenase-1 and -2 Play Contrasting Roles in *Listeria monocytogenes*
703 Stimulated Immunity. J Immunol. 2018;
- 704 15. Harizi H, Corcuff J-B, Gualde N. Arachidonic-acid-derived eicosanoids: roles in biology
705 and immunopathology. Trends Mol Med. 2008 Oct 1;14(10):461–9.
- 706 16. Hara S, Kamei D, Sasaki Y, Tanemoto A, Nakatani Y, Murakami M. Prostaglandin E
707 synthases: Understanding their pathophysiological roles through mouse genetic models.
708 Biochimie. 2010;92:651–9.
- 709 17. Smith WL, Michael Garavito R, DeWitt DL. Prostaglandin endoperoxide H synthases
710 (cyclooxygenases)-1 and -2. J Biol Chem. 1996 Dec 27;271(52):33157–60.

- 711 18. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LBA, et al.
712 Cyclooxygenase in biology and disease. *FASEB J.* 1998;12:1063–73.
- 713 19. Hara S. Prostaglandin terminal synthases as novel therapeutic targets. *Proc Japan Acad*
714 *Ser B, Phys Biol Sci.* 2017;703–23.
- 715 20. Aoshi T, Carrero JA, Konjufca V, Koide Y, Unanue ER, Miller MJ. The cellular niche of
716 *Listeria monocytogenes* infection changes rapidly in the spleen. *Eur J Immunol.* 2009
717 Feb;39(2):417–25.
- 718 21. Noor S, Goldfine H, Tucker DE, Suram S, Lenz LL, Akira S, et al. Activation of
719 Cytosolic Phospholipase A 2 in Resident Peritoneal Macrophages by *Listeria*
720 *monocytogenes* Involves Listeriolysin O and TLR2 *. 2007;
- 721 22. Leslie CC. Cytosolic phospholipase A2: Physiological function and role in disease
722 [Internet]. Vol. 56, *Journal of Lipid Research*. American Society for Biochemistry and
723 *Molecular Biology Inc.*; 2015. p. 1386–402.
- 724 23. von Moltke J, Trinidad NJ, Moayeri M, Kintzer AF, Wang SB, van Rooijen N, et al.
725 Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. *Nature.*
726 2012/08/21. 2012 Aug 19;490(7418):107–11.
- 727 24. Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, LUCKETT W, et al. *Listeria*-
728 based cancer vaccines that segregate immunogenicity from toxicity. *Proc Natl Acad Sci U*
729 *S A.* 2004 Sep 21;101(38):13832–7.
- 730 25. Kozak KR, Crews BC, Ray JL, Tai HH, Morrow JD, Marnett LJ. Metabolism of
731 Prostaglandin Glycerol Esters and Prostaglandin Ethanolamides in Vitro and in Vivo. *J*
732 *Biol Chem.* 2001 Oct 5;276(40):36993–8.
- 733 26. Abram CL, Roberge GL, Hu Y, Lowell CA. Comparative analysis of the efficiency and

- 734 specificity of myeloid-Cre deleting strains using ROSA-EYFP reporter mice. *J Immunol*
735 *Methods*. 2014;408:89–100.
- 736 27. Pirgova G, Chauveau A, MacLean AJ, Cyster JG, Arnon TI. Marginal zone SIGN-R1+
737 macrophages are essential for the maturation of germinal center B cells in the spleen. *Proc*
738 *Natl Acad Sci U S A*. 2020 Jun 2;117(22):12295–305.
- 739 28. van Rooijen N, Kors N, Kraal G. Macrophage subset repopulation in the spleen:
740 differential kinetics after liposome-mediated elimination. *J Leu*. 1989;45(2):97–104.
- 741 29. Backer R, Schwandt T, Greuter M, Oosting M, Jüngerkes F, Tüting T, et al. Effective
742 collaboration between marginal metallophilic macrophages and CD8 + dendritic cells in
743 the generation of cytotoxic T cells. 2010;107(1):216–21.
- 744 30. Alzuguren P, Hervas-Stubbs S, Gonzalez-Aseguinolaza G, Poutou J, Fortes P, Mancheno
745 U, et al. Transient depletion of specific immune cell populations to improve adenovirus-
746 mediated transgene expression in the liver. *Liver Int*. 2014;
- 747 31. Crimmins GT, Herskovits AA, Rehder K, Sivick KE, Lauer P, Dubensky TW, et al.
748 *Listeria monocytogenes* multidrug resistance transporters activate a cytosolic surveillance
749 pathway of innate immunity. *Proc Natl Acad Sci U S A*. 2008 Jul 22;105(29):10191–6.
- 750 32. Huynh TAN, Woodward JJ. Too much of a good thing: Regulated depletion of c-di-AMP
751 in the bacterial cytoplasm. Vol. 30, *Current Opinion in Microbiology*. Elsevier Ltd; 2016.
752 p. 22–9.
- 753 33. McFarland AP, Luo S, Ahmed-Qadri F, Zuck M, Thayer EF, Goo YA, et al. Sensing of
754 Bacterial Cyclic Dinucleotides by the Oxidoreductase RECON Promotes NF- κ B
755 Activation and Shapes a Proinflammatory Antibacterial State. *Immunity*. 2017 Mar
756 21;46(3):433–45.


- 757 34. Woodward JJ, Iavarone AT, Portnoy DA. c-di-AMP Secreted by Intracellular *Listeria*
758 *monocytogenes* Activates a Host Type I Interferon Response. *Science* (80-). 2010 Jun
759 25;328(5986):1703–5.
- 760 35. Sauer J, Sotelo-Troha K, von Moltke J, Monroe KM, Rae CS, Brubaker SW, et al. The N-
761 Ethyl-N-Nitrosourea-Induced Goldenticket Mouse Mutant Reveals an Essential Function
762 of Sting in the In Vivo Interferon Response to *Listeria monocytogenes* and Cyclic
763 Dinucleotides. *Infect Immun*. 2011 Feb 1;79(2):688–94.
- 764 36. Coulombe F, Jaworska J, Verway M, Tzelepis F, Massoud A, Gillard J, et al. Targeted
765 prostaglandin E2 inhibition enhances antiviral immunity through induction of type I
766 interferon and apoptosis in macrophages. *Immunity*. 2014/04/15. 2014 Apr 17;40(4):554–
767 68.
- 768 37. Mayer-Barber KD, Andrade BB, Oland SD, Amaral EP, Barber DL, Gonzales J, et al.
769 Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon
770 crosstalk. *Nature*. 2014 Jul 3;511(7507):99–103.
- 771 38. von Moltke J, Ayres JS, Kofoed EM, Chavarria-Smith J, Vance RE. Recognition of
772 bacteria by inflammasomes. *Annu Rev Immunol*. 2012/12/12. 2013;31:73–106.
- 773 39. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. *Annu Rev*
774 *Immunol*. 2009;27:229–65.
- 775 40. McDougal CE, Sauer JD. *Listeria monocytogenes*: The impact of cell death on infection
776 and immunity [Internet]. Vol. 7, *Pathogens*. MDPI AG; 2018. p. 8.
- 777 41. Sauer J, Witte CE, Zemansky J, Hanson B, Lauer P, Portnoy DA. *Listeria monocytogenes*
778 triggers AIM2-mediated pyroptosis upon infrequent bacteriolysis in the macrophage
779 cytosol. *Cell Host Microbe*. 2010/04/27. 2010;7(5):412–9.

- 780 42. Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, et al.
781 AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with
782 ASC. *Nature*. 2009 Mar 26;458(7237):514–8.
- 783 43. Fernandes-Alnemri T, Yu J-WW, Datta P, Wu J, Alnemri ES. AIM2 activates the
784 inflammasome and cell death in response to cytoplasmic DNA. *Nature*. 2009 Mar
785 26;458(7237):509–13.
- 786 44. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering
787 activation of inflammatory caspases and processing of proIL-beta. *Mol Cell*. 2002/08/23.
788 2002 Aug;10(2):417–26.
- 789 45. Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, et al. Cleavage of GSDMD by
790 inflammatory caspases determines pyroptotic cell death. *Nature*. 2015 Sep
791 16;526(7575):660–5.
- 792 46. Kayagaki N, Stowe IB, Lee BL, O'Rourke K, Anderson K, Warming S, et al. Caspase-11
793 cleaves gasdermin D for non-canonical inflammasome signalling. *Nature*. 2015 Sep
794 16;526(7575):666–71.
- 795 47. Rauch I, Deets KA, Ji DX, von Moltke J, Tenthorey JL, Lee AY, et al. NAIP-NLRC4
796 Inflammasomes Coordinate Intestinal Epithelial Cell Expulsion with Eicosanoid and IL-
797 18 Release via Activation of Caspase-1 and -8. *Immunity*. 2017 Apr 18;46(4):649–59.
- 798 48. Glomski IJ, Decatur AL, Portnoy DA. *Listeria monocytogenes* mutants that fail to
799 compartmentalize listerolysin O activity are cytotoxic, avirulent, and unable to evade host
800 extracellular defenses. *Infect Immun*. 2003 Dec;71(12):6754–65.
- 801 49. Glomski IJ, Gedde M, Tsang A, Swanson J, Portnoy D. The *Listeria monocytogenes*
802 hemolysin has an acidic pH optimum to compartmentalize activity and prevent damage to

- 803 infected host cells. *J Cell Biol.* 2002/03/20. 2002 Mar 18;156(6):1029–38.
- 804 50. Schnupf P, Portnoy DA, Decatur AL. Phosphorylation, ubiquitination and degradation of
805 listeriolysin O in mammalian cells: role of the PEST-like sequence. *Cell Microbiol.*
806 2006;8(2):353–64.
- 807 51. Nguyen BN, Portnoy DA. An Inducible Cre-lox System to Analyze the Role of LLO in
808 *Listeria monocytogenes* Pathogenesis. *Toxins (Basel).* 2020 Jan 7;12(1).
- 809 52. Brock TG, Peters-Golden M. Activation and Regulation of Cellular Eicosanoid
810 Biosynthesis. *Sci World J.* 2007;7:1273–84.
- 811 53. Tokudome S, Sano M, Shinmura K, Matsubashi T, Morizane S, Moriyama H, et al.
812 Glucocorticoid protects rodent hearts from ischemia/reperfusion injury by activating
813 lipocalin-type prostaglandin D synthase-derived PGD₂ biosynthesis. *J Clin Invest.* 2009
814 Jun 1;119(6):1477–88.
- 815 54. Biringer RG. The Enzymes of the Human Eicosanoid Pathway. *Res Rep Med Sci.* 2018;
- 816 55. Xiao L, Ornatowska M, Zhao G, Cao H, Yu R, Deng J, et al. Lipopolysaccharide-Induced
817 Expression of Microsomal Prostaglandin E Synthase-1 Mediates Late-Phase PGE₂
818 Production in Bone Marrow Derived Macrophages. Zhang L, editor. *PLoS One.* 2012 Nov
819 30;7(11):e50244.
- 820 56. Duncan KD, Fang R, Yuan J, Chu RK, Dey SK, Burnum-Johnson KE, et al. Quantitative
821 Mass Spectrometry Imaging of Prostaglandins as Silver Ion Adducts with Nanospray
822 Desorption Electrospray Ionization. *Anal Chem.* 2018 Jun 19;90(12):7246–52.
- 823 57. Markovič T, Jakopin Ž, Dolenc MS, Mlinarič-Raščan I. Structural features of subtype-
824 selective EP receptor modulators. Vol. 22, *Drug Discovery Today.* Elsevier Ltd; 2017. p.
825 57–71.


- 826 58. Abramovitz M, Adam M, Boie Y, Carrière M-C, Denis D, Godbout C, et al. The
827 utilization of recombinant prostanoid receptors to determine the affinities and selectivities
828 of prostaglandins and related analogs. *Biochim Biophys Acta - Mol Cell Biol Lipids*. 2000
829 Jan 17;1483(2):285–93.
- 830 59. Krause P, Bruckner M, Uermö Si C, Singer E, Groettrup M, Legler DF. Prostaglandin E 2
831 enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and
832 4-1BBL on dendritic cells. 2009;
- 833 60. Sheppe AEF, Kummari E, Walker A, Richards A, Hui WW, Lee JH, et al. PGE2
834 Augments Inflammasome Activation and M1 Polarization in Macrophages Infected With
835 *Salmonella Typhimurium* and *Yersinia enterocolitica*. *Front Microbiol*. 2018 Oct 31;9.
- 836 61. Mauel J, Ransijn A, Corradin SB, Buchmuller-Rouiller Y. Effect of PGE2 and of agents
837 that raise cAMP levels on macrophage activation induced by IFN- γ and TNF- α . *J Leukoc*
838 *Biol*. 1995;58(2):217–24.
- 839 62. Scandella E, Men Y, Gillessen S, Förster R, Groettrup M. Prostaglandin E2 is a key factor
840 for CCR7 surface expression and migration of monocyte-derived dendritic cells. *Blood*.
841 2002 Aug 15;100(4):1354–61.
- 842 63. Legler DF, Krause P, Scandella E, Singer E, Groettrup M. Prostaglandin E 2 Is Generally
843 Required for Human Dendritic Cell Migration and Exerts Its Effect via EP2 and EP4
844 Receptors . *J Immunol*. 2006 Jan 15;176(2):966–73.
- 845 64. Panzer U, Uguccioni M. Prostaglandin E 2 modulates the functional responsiveness of
846 human monocytes to chemokines.
- 847 65. Tajima T, Murata T, Aritake K, Urade Y, Hirai H, Nakamura M, et al. Lipopolysaccharide
848 induces macrophage migration via prostaglandin D 2 and prostaglandin E2. *J Pharmacol*

- 849 Exp Ther. 2008 Aug 1;326(2):493–501.
- 850 66. Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, et al. Prostaglandin E 2-EP4
851 signaling promotes immune inflammation through T H 1 cell differentiation and T H 17
852 cell expansion. 2009;
- 853 67. Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, et al.
854 Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E
855 synthase. Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):9044–9.
- 856 68. Nakanishi M, Montrose DC, Clark P, Nambiar PR, Belinsky GS, Claffey KP, et al.
857 Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis. Cancer Res. 2008 May
858 1;68(9):3251–9.
- 859 69. Nakanishi M, Menoret A, Tanaka T, Miyamoto S, Montrose DC, Vetta A, et al. Selective
860 PGE 2 suppression inhibits colon carcinogenesis and modifies local mucosal immunity.
861 Cancer Prev Res. 2011 Aug 1;4(8):1198–208.
- 862 70. Lutz MB, Kukutsch N, Ogilvie ALJ, Rößner S, Koch F, Romani N, et al. An advanced
863 culture method for generating large quantities of highly pure dendritic cells from mouse
864 bone marrow. J Immunol Methods. 1999 Feb 1;223(1):77–92.
- 865 71. Chen JH, Perry CJ, Tsui Y-C, Staron MM, Parish IA, Dominguez CX, et al. Prostaglandin
866 E2 and programmed cell death 1 signaling coordinately impair CTL function and survival
867 during chronic viral infection. Nat Med. 2015 Mar 23;21(4):327–34.
- 868
- 869




870

871 **Fig 1**




872

873 Fig 2




874

875 **Fig 3**



876

877 Fig 4



878

879 **Fig 5**

880 **Figure Legends**

881 **Fig 1. PAM-primed BMDMs and BMDCs express PGE₂ after cytosolic infection with *L.***

882 ***monocytogenes*.** Wild-type or COX-2^{-/-} BMDMs or BMDCs were infected with indicated strains
883 of *L. monocytogenes* at an MOI of 10 +/- the TLR2 agonist PAM3CSK4 and assessed 6hpi for
884 expression of *Ptgs2* (encoding COX-2) and *Ptges* (encoding mPGES-1) by qRT PCR (A-B) or
885 COX-2 protein by western blot (C). Supernatant was harvested and assessed for PGE₂ by mass
886 spectrometry (D). Mass spectrometry data was normalized to d-PGE₂ and fold change is relative
887 to PBS treated controls. Data are a combination of at least two independent experiments (A,B, D,
888 and western blot quantification), or a representative of at least two independent experiments
889 (western blot image). Significance was determined by a one-way ANOVA with Bonferroni's
890 correction. **p* < 0.05, ***p* < 0.01, ****p* < 0.001, *****p* < 0.0001

891

892 **Fig 2. Cytosolic access is necessary for *L. monocytogenes*-stimulated PGE₂ production *in***

893 ***vivo*.** C57BL/6 mice were infected with 10⁵ wild-type or 10⁷ Δ *hly* *L. monocytogenes*. 12hpi
894 spleens were harvested for eicosanoid extraction and mass spectrometry (A) and livers were
895 harvested for bacterial burdens (B). Data are representative of two independent experiments.
896 Mass spectrometry data was normalized to d-PGE₂ levels and fold change is compared to PBS
897 controls. Significance was determined by a one-way ANOVA with Bonferroni's correction.
898 *****p* < 0.0001

899

900 **Fig 3. CD11c⁺ and Lyz2⁺ cells contribute to PGE₂ production *in vivo*.** Indicated strains of

901 mice were infected with 10⁷ LADD *L. monocytogenes*. 12hpi spleens were harvested and
902 assessed for PGE₂ by mass spectrometry. Data was normalized to d-PGE₂ levels and percent

903 change is compared to *L. monocytogenes*-infected controls (A). Indicated strains of mice were
904 infected with 10^7 LADD *L. monocytogenes*. 7dpi splenocytes were examined for B8R-specific
905 CD8⁺ T-cell responses. %IFN γ (B) or number IFN γ (C) per spleen was assessed. Data shown are
906 representative of two independent experiments. Significance was determined by a one-way
907 ANOVA with Bonferroni's correction (A). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

908

909 **Fig 4. Deletion of COX-2 in both CD11c⁺ and Lyz2⁺ cells further reduces PGE₂ production.**

910 Indicated strains of mice were infected with 10^7 LADD *L. monocytogenes*. 12hpi spleens were
911 harvested and assessed for PGE₂ by mass spectrometry. Data was normalized to d-PGE₂ levels
912 and percent change is compared to *L. monocytogenes*-infected controls (A). Indicated strains of
913 mice were infected with 10^7 LADD *L. monocytogenes*. 7dpi splenocytes were examined for
914 B8R-specific CD8⁺ T-cell responses. %IFN γ (B) or number IFN γ (C) per spleen was assessed.
915 Data shown are representative of two independent experiments of 3-5 mice per group.
916 Significance was determined by a one-way ANOVA with Bonferroni's correction (A) or a
917 Mann-Whitney *U* test (B-C). * $p < 0.05$, ** $p < 0.01$

918

919 **Fig 5. Phagocyte depletion eliminates PGE₂ production.** C57BL/6 mice were dosed with
920 200 μ L clodronate, liposome control (encapsome), or PBS 24 hours prior to immunization with
921 10^7 LADD *L. monocytogenes*. 12hpi spleens were harvested and assessed for PGE₂ by mass
922 spectrometry. Data was normalized to d-PGE₂ levels and percent change is compared to *L.*
923 *monocytogenes*-infected controls (A). Livers were harvested concurrently and assessed for
924 bacterial burdens (B). C57BL/6 mice were immunized with 10^7 LADD *L. monocytogenes*. 3 and
925 10hpi spleens were harvested, cryosections were cut, and sections were stained for *L.*

926 *monocytogenes* (Lm), COX-2, and MARCO (C). Yellow arrows represent colocalization of *L.*
927 *monocytogenes*, COX-2, and MARCO (C). Colocalization coefficients (Pearson's correlation) of
928 COX-2 and MARCO were calculated (D). Data shown are representative of at least two
929 independent experiments. Significance was determined by a one-way ANOVA with Bonferroni's
930 correction (A) or a Mann-Whitney *U* test (D). * $p < 0.05$, ** $p < 0.01$, **** $p < 0.0001$